年龄、性别、族裔、社会经济剥夺与新型药物对新西兰多发性骨髓瘤患者总生存的影响
该研究利用新西兰全国联动数据,评估2004至2016年确诊骨髓瘤患者的发生率、患病率及总生存(OS)。粗发生率从5·42升至8·47/100 000,年龄标化率从4·01升至5·28/100 000;2016年12月估计患病率为37·8/100 000。中位OS从2004-2007年的34·8个月增至2012-2016年的50·7个月;2011年硼替佐米公共资助后,>70岁患者中位OS从19·4个月增至28·6个月,≤70岁未接受自体干细胞移植(ASCT)者从49·1个月增至62·7个月,但接受ASCT者中位OS无差异。社会经济剥夺为独立不良预后因素;硼替佐米资助后,毛利/太平洋岛民及最贫困五分位人群生存无改善。
要点
- 骨髓瘤粗发生率从5·42升至8·47/100 000,年龄标化率从4·01升至5·28/100 000。
- 中位OS从2004-2007年的34·8个月增至2012-2016年的50·7个月。
- 硼替佐米资助后,毛利/太平洋岛民及最贫困人群生存无改善。
核心结论
- 骨髓瘤发生率增加且生存改善,但毛利/太平洋岛民族裔及社会经济剥夺对生存有负面影响。
研究设计与样本
- 利用新西兰全国联动数据,评估2004至2016年确诊骨髓瘤患者的发生率、患病率及总生存。
主要发现
- 粗发生率从5·42升至8·47/100 000,年龄标化率从4·01升至5·28/100 000。
- 2016年12月估计患病率为37·8/100 000。
- 中位OS从2004-2007年的34·8个月(95% CI 31·4, 39·3)增至2012-2016年的50·7个月(95% CI 48·5, 57·3)。
- 硼替佐米资助后,>70岁患者中位OS从19·4个月(95% CI 16·3, 23·1)增至28·6个月(95% CI 24·5, 32·8)。
- ≤70岁未接受ASCT者中位OS从49·1个月(95% CI 37·1, 57·5)增至62·7个月(95% CI 51·7, 79·2),接受ASCT者中位OS无差异。
临床怎么用
- 关注社会经济剥夺作为骨髓瘤独立不良预后因素。
- 硼替佐米资助后毛利/太平洋岛民及最贫困人群生存未改善,需针对性干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The impact of age, ethnicity and socio-economic deprivation in the era of novel anti-myeloma agents is unclear. Using linked national data from New Zealand, we evaluated the incidence, prevalence and overall survival (OS) of individuals who were diagnosed with myeloma between 2004 and 2016. The crude incidence rate increased from 5·42 to 8·47/100 000 and the age-standardised rate increased from 4·01 to 5·28/100 000. The estimated prevalence in December 2016 was 37·8/100 000. Median OS increased from 34·8 (95% CI 31·4, 39·3) months in 2004-2007 to 50·7 (48·5, 57·3) months in 2012-2016. Following the public funding of bortezomib in 2011, the median OS for individuals >70 years increased from 19·4 (16·3, 23·1) to 28·6 (24·5, 32·8) months. For those ≤70 years of age who did not have autologous stem cell transplantation (ASCT), median OS increased from 49·1 (37·1, 57·5) to 62·7 (51·7, 79·2) months; but for those who had ASCT, there was no difference in median OS. Socio-economic deprivation was an independent adverse prognostic factor. Māori/Pasifika and those in the most deprived quintile experienced no improvement in survival after bortezomib was funded. Our study confirms the increasing incidence and improving survival of myeloma patients, and the negative impact of Māori/Pasifika ethnicity and socio-economic deprivation on survival.
引用
- Chan HSH, Milne RJ. Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand. Br J Haematol. 2019. PMID: 31584720. doi:10.1111/bjh.16238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。